Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Antitumor cell activity in glioblastoma is controlled by blocking the triggering receptor expressed on myeloid cells 2.

2.

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

3.

For MDS-Related Anemia, Telomerase Inhibitor Approved.

4.

Researchers explore e-bikes for cancer recovery

5.

Men With Prostate Cancer Experience Less Hot Flashes When Using an Affordable Drug.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot